Clover Biopharmaceuticals

Overview
Activities
News
Biosimilars?
Product stageSegments
Growth
?
Diversified Drug Developers
?

Clover Biopharmaceuticals is a global commercial-stage biotechnology company focused on developing innovative vaccines and biologic therapeutics. The company utilizes its proprietary Trimer-Tag vaccine technology platform to create novel vaccines and biologic therapies. Clover's lead product is SCB-2019, a Covid-19 vaccine candidate based on a stabilized trimeric form of the SARS-CoV-2 spike protein. In clinical trials, SCB-2019 demonstrated 100% efficacy against severe Covid-19 and hospitalization. The vaccine also showed 84% efficacy in preventing household transmission of SARS-CoV-2. In December 2022, Clover's Covid-19 vaccine received emergency use authorization in China. The company launched the vaccine in China in February 2023 as part of the country's second booster dose campaign targeting older adults and high-risk groups.

Beyond Covid-19, Clover is developing other vaccine candidates, including SCB-1019, a bivalent RSV vaccine that entered Phase I clinical trials in December 2023. The company is also advancing SCB-219 million, a treatment for chemotherapy-induced thrombocytopenia that showed promising results in Phase I trials in December 2023. Clover has expanded its research and development capabilities, beginning construction on a new R&D center in Shanghai in January 2022. The 25,000 square meter facility is expected to include preclinical research labs, process development labs, and a GMP pilot manufacturing plant.

Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Nan Yan Xian Tian Fu Avenue Chengdu CHN
Founded year:
2007
Employees:
501-1,000
IPO status:
Public
Total funding:
USD 343.7 mn
Last Funding:
USD 36.9 mn (Post IPO Equity; Nov 2021)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.